The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Challenges that remain in treating older patients with Hodgkin lymphoma
In this video, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, highlights the challenges of treating older patients with Hodgkin lymphoma, emphasizing the need to balance the benefits of novel agents with the increased risk of side effects and toxicities, particularly neuropathy and endocrinopathies. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the challenges that remain are while you’d like to use these new agents, we’d like to be able to give it for a longer period of time to get a better outcome. Older patients tolerate some of these agents less well and the longer you give it the more side effects you get. So the challenges with neuropathy and endocrinopathies that come with brentuximab vedotin and nivolumab respectively, those remain substantial challenges...
I think the challenges that remain are while you’d like to use these new agents, we’d like to be able to give it for a longer period of time to get a better outcome. Older patients tolerate some of these agents less well and the longer you give it the more side effects you get. So the challenges with neuropathy and endocrinopathies that come with brentuximab vedotin and nivolumab respectively, those remain substantial challenges. Also some elderly patients are so fragile and frail that even using two of those drugs together is hard. So I think the challenge is going to be how to find the right regimen with the right degree of intensity, the right duration of therapy and minimizing those side effects and toxicities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
